98%
921
2 minutes
20
Purpose: To evaluate variations in acquisition and processing protocols for four of the most common PET/CT examinations in Dutch hospitals: FDG-WB, [F]F-PSMA, [Ga]Ga-PSMA, and FDG-Brain.
Methods: All nuclear medicine departments in the Netherlands with a PET/CT scanner were invited to participate in a survey about acquisition and processing protocols for FDG-WB, [F]F-PSMA, [Ga]Ga-PSMA, and FDG-Brain PET/CT examinations. The survey collected data on injected activity, acquisition times, and reconstruction/post-processing settings. From these data, we analyzed the weight-dependent injected activity, acquisition count statistics, and correlations with scanner performance (NEMA sensitivity).
Results: A total of 42 hospitals responded (including all Dutch University Medical Centers), providing data from 58 PET/CT systems spanning 11 different models from 4 vendors. Injected activity and scan duration varied widely across hospitals, even for the same scanner model and examination type. A moderate negative correlation was observed between scanner sensitivity and the normalized injected activity × scan duration product for FDG-WB (R = 0.50, slope = - 186.5) and FDG-brain (R = 0.33, slope = - 180.8), suggesting that hospitals using higher-sensitivity scanners tend to reduce either injected activity or scan duration to maintain comparable acquisition counts. For [F]F-PSMA (R = 0.24, slope = - 62.6), the trend was less pronounced, indicating greater variability in how PET/CT centers adjust injected activity and scan duration for these tracers. In contrast, for [ Ga]Ga-PSMA (R = 0.04, slope = - 28.3), no significant correlation was found, suggesting that scanner sensitivity plays a minimal role in protocol selection for these examinations. The observed variations in injected activity led to differences in patient radiation dose by a factor of 4 for FDG-WB, more than a factor of 10 for PSMA, and a factor of 5 for FDG-brain scans. These differences persist even after accounting for scan duration, scanner sensitivity, and overlap between scanning positions, highlighting substantial inconsistencies in PET/CT imaging protocols across Dutch hospitals.
Conclusion: The main objective of this survey was to determine the current state of practice in the Netherlands for three common PET/CT examinations. We observed variations in the injected activity for all PET/CT exam types, even within the same scanner model, that cannot be explained by taking into account differences in scanning times or uptake times. The direct implication of the observed variation in injected activity is a similar variation in radiation dose to the patient. We observed differences in dose to the patient of up to a factor 4 for FDG-WB, more than a factor of 5for [F]F-PSMA, a factor of 4 for [ Ga]Ga-PSMA, and up to a factor of 5 for FDG-brain scans. Variations in count statistics, reconstruction, and processing settings for similar-weight patients on comparable PET/CT systems should be further investigated for their impact on lesion detectability.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179025 | PMC |
http://dx.doi.org/10.1186/s40658-025-00770-3 | DOI Listing |
Mol Ther Methods Clin Dev
June 2025
Eisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Liver-humanized chimeric mice (PXB-mice) are widely utilized for predicting human pharmacokinetics (PK) and as human disease models. However, residual metabolic activity of mouse hepatocytes in chimeric mice can interfere with accurate human PK estimation. Lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) treatment makes it possible to eliminate the shortcomings of chimeras and create new models.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
June 2025
Shanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.
View Article and Find Full Text PDFInt J Pharm X
June 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Ultra-sensitive pH-responsive drug delivery system designed to operate within the slightly acidic microenvironment of tumors are highly desired for hydrogel applications in cancer therapy. In this study, 4-Formylbenzoic acid modified polyvinyl alcohol (PVA-FBA, PF) was synthesized and utilized as a carrier for encapsulating the anticancer drug Doxorubicin (Dox). This was subsequently crosslinked with polyethylenimine (PEI) via benzoic-imine bond to form drug-loaded PVA-FBA/PEI hydrogel (D-PFP).
View Article and Find Full Text PDFBiomater Biosyst
September 2025
ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Introduction: The airway mucosa plays a crucial role in protection and various physiological functions. Current methods for restoring airway mucosa, such as myocutaneous flaps or split skin grafts, create a stratified squamous layer that lacks the cilia and mucus-secreting glands of the native columnar-lined airway. This study examines the application of various injectable biopolymers as active molecules for a potential approach to regenerating laryngeal epithelial tissue.
View Article and Find Full Text PDFNatl Sci Rev
September 2025
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China.
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising resolution for solid tumors, but its corresponding clinical translation has been hindered by unsatisfactory therapeutic potency and severe cytokine release syndrome. Herein, tetracycline (Tet)-On inducible human epidermal growth factor receptor 1 (HER1)-targeted CAR-T (Tet-HER1-CAR-T) cells were engineered to enable spatially selective activation at tumor sites by doxycycline (Doxy), which is delivered by pH-responsive stealth liposomal calcium carbonate nanoparticles (Doxy@CaCO-PEG). Compared with the intravenous administration of conventional HER1-CAR-T cells and Tet-HER1-CAR-T cells activated by free Doxy, concurrent intravenous administration of Tet-HER1-CAR-T cells and Doxy@CaCO-PEG leads to the localized tumor activation of Tet-HER1-CAR-T cells and reduced systemic secretion of inflammatory cytokines.
View Article and Find Full Text PDF